Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Interferon therapy prolonged life expectancy among chronic hepatitis C patients.

Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, Yamada G, Yokosuka O, Shiratori Y, Omata M.

Gastroenterology. 2002 Aug;123(2):483-91.

PMID:
12145802
2.

Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death.

Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, Kawata S, Tanaka E, Hino K, Hayashi K, Tamura S, Itoh Y, Kiyosawa K, Kakumu S, Okita K, Hayashi N.

J Viral Hepat. 2004 Mar;11(2):148-56.

PMID:
14996350
3.

Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study.

Imazeki F, Yokosuka O, Fukai K, Saisho H.

Hepatology. 2003 Aug;38(2):493-502.

PMID:
12883494
4.

Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response.

Imai Y, Kasahara A, Tanaka H, Okanoue T, Hiramatsu N, Tsubouchi H, Yoshioka K, Kawata S, Tanaka E, Hino K, Hayashi K, Tamura S, Itoh Y, Sasaki Y, Kiyosawa K, Kakumu S, Okita K, Hayashi N.

J Gastroenterol. 2004 Nov;39(11):1069-77.

PMID:
15580400
5.

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M.

Ann Intern Med. 1999 Aug 3;131(3):174-81.

PMID:
10428733
6.
7.

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.

Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M.

Ann Intern Med. 2000 Apr 4;132(7):517-24.

PMID:
10744587
8.

Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.

Omata M, Yoshida H, Shiratori Y.

Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S141-3. Review.

PMID:
16234063
9.

Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.

Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, Kudo M, Sato T, Chiba T.

Ann Intern Med. 2007 May 1;146(9):649-56.

PMID:
17470833
10.

Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.

Imai Y, Tamura S, Tanaka H, Hiramatsu N, Kiso S, Doi Y, Inada M, Nagase T, Kitada T, Imanaka K, Fukuda K, Takehara T, Kasahara A, Hayashi N.

J Viral Hepat. 2010 Mar;17(3):185-91. doi: 10.1111/j.1365-2893.2009.01163.x. Epub 2009 Aug 26.

PMID:
19709362
11.

Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.

Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, Borzio M, Redaelli A, Chiesa A, Silini EM, Almasio PL, Maisonneuve P.

Am J Gastroenterol. 2009 May;104(5):1147-58. doi: 10.1038/ajg.2009.31. Epub 2009 Apr 7.

PMID:
19352340
12.

Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.

Huang JF, Yu ML, Lee CM, Dai CY, Hou NJ, Hsieh MY, Wang JH, Lu SN, Sheen IS, Lin SM, Chuang WL, Liaw YF.

Aliment Pharmacol Ther. 2007 May 1;25(9):1029-37.

13.

Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.

Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, Tsubouchi H, Kiyosawa K, Kakumu S, Okita K, Hayashi N, Okanoue T.

Cancer. 2004 Oct 1;101(7):1616-22.

14.

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL.

Hepatology. 2004 Mar;39(3):804-10.

PMID:
14999700
15.

Survival in hepatitis C and HIV co-infection: a cohort study of hospitalized veterans.

El-Serag HB, Giordano TP, Kramer J, Richardson P, Souchek J.

Clin Gastroenterol Hepatol. 2005 Feb;3(2):175-83.

PMID:
15704052
16.

Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy.

Okanoue T, Minami M, Makiyama A, Sumida Y, Yasui K, Itoh Y.

Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S89-91.

PMID:
16234069
17.

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D, Nawrocki M, Kruska L, Hensel F, Petry W, Häussinger D.

Hepatology. 1998 Dec;28(6):1687-95.

PMID:
9828236
18.
19.

Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.

Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, Watanabe H.

J Gastroenterol. 2005 Feb;40(2):148-56.

PMID:
15770398
20.

Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.

Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M.

Ann Intern Med. 2003 Feb 18;138(4):299-306.

PMID:
12585827

Supplemental Content

Support Center